My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Darapladib (SB-480848)
    Darapladib (SB-480848)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0844
    CAS #: 356057-34-6; Purity ≥98%

    Description:  Darapladib (formerly also known as SB-480848) is a novel, potent and reversible lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor with IC50 of 0.25 nM, which is in Phase 3 trials. 

    References: Bioorg Med Chem Lett. 2003;13(6):1067-70; Nat Med. 2008;14(10):1059-66; J Alzheimers Dis. 2013;35(1):179-98.

    Related CAS: 1389264-17-8 (Darapladib-impurity)

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Citation of InvivoChem Larotrectinib (V2599) by Cell (2020) 183(5):1202-1218.e25
    • Citation of InvivoChem BMH-21 (V1435) by Cell Stem Cell 2020, 26(6): 845-861.e12.
    • Citation of InvivoChem BMS-582949 (V2668) by Cells 2020, 9(6):1472. doi: 10.3390/cells90614
    • Citation of InvivoChem Resveratrol (V0430) by Arterioscler Thromb Vasc Biol 2020; ATVBAHA12
    • Citation of InvivoChem venetoclax and S63845 (V2797) by Cell Death and Disease (2020) 11:316.
    • Citation of InvivoChem Belumosudil (KD025) by Am J Physiol Renal Physiol. 2019; 317(4):F839-F851.
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)666.77
    FormulaC36H38F4N4O2S
    CAS No.356057-34-6
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 100 mg/mL (150.0 mM)
    Water: <1 mg/mL
    Ethanol: 100 mg/mL (150.0 mM)
    Other infoChemical Name: N-[2-(diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-1H-Cyclopentapyrimidine-1-acetamide
    InChi Key: WDPFJWLDPVQCAJ-UHFFFAOYSA-N
    InChi Code: InChI=1S/C36H38F4N4O2S/c1-3-42(4-2)20-21-43(22-25-8-12-27(13-9-25)28-14-16-29(17-15-28)36(38,39)40)33(45)23-44-32-7-5-6-31(32)34(46)41-35(44)47-24-26-10-18-30(37)19-11-26/h8-19H,3-7,20-24H2,1-2H3
    SMILES Code: O=C(N(CCN(CC)CC)CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)CN(C3=C4CCC3)C(SCC5=CC=C(F)C=C5)=NC4=O
    SynonymsDarapladib; SB-480848;SB 480848; SB480848


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity:  During the copper catalysed oxidation of human LDL, Darapladib prevents the production of lyso-PtdCho with IC50 of 4 nM and subsequent monocyte chemotaxis with IC50 of 4 nM.


    Kinase Assay: Darapladib is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with IC50 of 0.25 nM.


    Cell Assay: Mechanistic studies using steady state and transient kinetics indicate Darapladib (SB-480848) to be a freely reversible, non-covalently bound, inhibitor of rhLp-PLA2 with a Ki of 110 pM and an off-rate of 27 min. Potent inhibition of the enzyme in whole human plasma is confirmed (IC50=5±2 nM). Furthermore, the presence of Darapladib during the copper catalysed oxidation of human LDL prevents the production of lyso-PtdCho (IC50=4±3 nM) and subsequent monocyte chemotaxis (IC50=4±1 nM). 

    In VivoIn the WHHL rabbits, Darapladib (30 mg/kg p.o.) exhibits excellent inhibition of Lp-PLA2 within the atherosclerotic plaque by 95%. Darapladib, as an inhibitor of Lp-PLA2, reduces development of advanced coronary atherosclerosis in diabetic and hypercholesterolemic (DMHC) pigs. In DMHC pigs, darapladib reduces the amount of IgG-immunopositive material that leaked into the brain and also the density of Aβ42-containing neurons.
    Animal modelWHHL rabbits 
    Formulation & DosageDissolved in 1% aq methylcellulose; 30 mg/kg; p.o.
    ReferencesBioorg Med Chem Lett. 2003 Mar 24;13(6):1067-70; Nat Med. 2008 Oct;14(10):1059-66; J Alzheimers Dis. 2013;35(1):179-98.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    Darapladib (SB-480848)

    Inhibition of Lp-PLA2 results in fewer lesion macrophages in coronary arteries. Nat Med. 2008 Oct;14(10):1059-66. 
     

    Darapladib (SB-480848)

    Inhibition of Lp-PLA2 results in fewer lesion macrophages in coronary arteries. Nat Med. 2008 Oct;14(10):1059-66.
     

    Darapladib (SB-480848)

    Influence of DM-HC induction and darapladib on arterial phospholipid composition. Nat Med. 2008 Oct;14(10):1059-66.


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?